Rising Ad Spending and Prescription Surge for Weight-Loss Diabetes Drugs
TL;DR
Drugmakers in the U.S. have spent nearly $500 million on advertising for obesity and diabetes treatments during the first seven months of this year, a 20% increase from the same period last year. The surge in ad spending is driven by the popularity of Novo Nordisk's diabetes drug Ozempic and weight loss drug Wegovy, both of which have seen high demand for their ability to aid weight loss. These drugs, along with other GLP-1 treatments, mimic a gut hormone to suppress appetite. The top four advertised drugs were Ozempic, Wegovy, Rybelsus, and Jardiance, accounting for three-quarters of total ad spending.
- Ad spending for obesity, diabetes drugs is soaring this year, as drugmakers shell out nearly $500 million CNBC
- Ozempic and Wegovy transform diabetes drugs into weight loss wonders FOX 26 Houston
- As Novo Nordisk boosts Wegovy, Ozempic ad spend, analysis finds 'a rising tide lifts all boats' for diabetes, weight-loss drugs FiercePharma
- New advice for doctors due to worldwide Ozempic shortage Australian Medical Association
- Prescriptions surge for Novo Nordisk's Ozempic and similar drugs Financial Times
Want the full story? Read the original reporting
Read on CNBC